Influenza virosomes in vaccine development

Methods in Enzymology

Volumn 373, Issue , 2003, Pages 74-91

  Huckriede, Anke ^a   Bungener, Laura ^a   Daemen, Toos ^a   Wilschut, Jan ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIPHTHERIA TOXOID; HEPATITIS A VACCINE; INFLUENZA VACCINE; MALARIA VACCINE; OVALBUMIN; PEPTIDE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOLIPID; TETANUS TOXOID; THREONYLTYROSYLGLUTAMINYLARGINYLTHREONYLARGINYLALANYLLEUCYLVALINE; UNCLASSIFIED DRUG; VIROSOME VACCINE; VIRUS PROTEIN; VIRUS PROTEIN HA; VIRUS PROTEIN NA; HLA ANTIGEN CLASS 2; VACCINE; VIROSOME;

ANIMAL CELL; ARTICLE; CYTOTOXIC T LYMPHOCYTE; EMBRYO; ENCAPSULATION; IMMUNOGENICITY; INFLUENZA VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANTIGEN PRESENTATION; ELECTRON MICROSCOPY; HUMAN; IMMUNOLOGY; INFLUENZA; ULTRASTRUCTURE;

INFLUENZA VIRUS;

ANTIGEN PRESENTATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLUENZA, HUMAN; MICROSCOPY, ELECTRON; T-LYMPHOCYTES, CYTOTOXIC; VACCINES; VIROSOMES;

EID: 1342269100     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(03)73005-5     Document Type: Article

References (43)

1. J. D. Almeida, C. M. Brand, D. C. Edwards, and T. D. Heath, Lancet 2, 899 (1975).
2. R. K. Scheule, Biochemistry 25, 4223 (1986).
3. B. Cornet, M. Vandenbranden, J. Cogniaux, L. Giurgea, D. Dekegel, and J. Ruysschaert, Biochem. Biophys. Res. Commun. 167, 222 (1990).
4. S. Bagai and D. P. Sarkar, Biochim. Biophys. Acta 1152, 15 (1993).
5. S. Grimaldi, D. Pozzi, A. Lisi, N. Santoro, and G. Ravagnan, J. Liposome Res. 3, 663 (1993).
6. M. Paternostre, M. Viard, O. Meyer, M. Ghanam, M. Ollivon, and R. Blumenthal, Biophys. J. 72, 1683 (1997).
7. R. A. Lamb and R. M. Krug, in "Virology" (D. M. Knipe and P. M. Howley, eds.), p. 1487. Lippincott Williams & Wilkins, Philadelphia, 2001.
8. D. C. Wiley and J. J. Skehel, J. Mol. Biol. 112, 343 (1977).
9. I. A. Wilson, J. J. Skehel, and D. C. Wiley, Nature 289, 366 (1981).
10. J. N. Varghese, W. G. Laver, and P. M. Colman, Nature 303, 35 (1983).
11. J. J. Skehel and D. C. Wiley, Annu. Rev. Biochem. 69, 531 (2000).
12. C. M. Carr and P. S. Kim, Cell 73, 823 (1993).
13. P. A. Bullough, F. M. Hughson, J. J. Skehel, and D. C. Wiley, Nature 371, 37 (1994).
14. K. S. Matlin, H. Reggio, A. Helenius, and K. Simons, J. Cell Biol. 91, 601 (1981).
15. T. Bizebard, B. Gigant, P. Rigolet, B. Rasmussen, O. Diat, P. Bosecke, S. A. Wharton, J. J. Skehel, and M. Knossow, Nature 376, 92 (1995).
16. T. Stegmann, H. W. M. Morselt, F. Booy, J. F. L. van Breemen, G. Scherphof, and J. Wilschut, EMBO J. 6, 2651 (1987).
17. V. Chams, P. Bonnafous, and T. Stegmann, FEBS Lett. 448, 28 (1999).
18. S. Günther-Ausborn, P. Schoen, I. Bartoldus, J. Wilschut, and T. Stegmann, J. Virol. 74, 2714 (2000).
19. P. Schoen, R. Bron, and J. Wilschut, J. Liposome Res. 3, 767 (1993).
20. R. Bron, A. Ortiz, and J. Wilschut, Biochemistry 33, 9110 (1994).
21. N. El Guink, R. M. Kris, G. Goodman-Snitkoff, S. J. P. A., and R. J. Mannino, Vaccine 7, 147 (1989).
22. R. Glück, R. Mischler, B. Finkel, J. U. Que, B. Scarpa, and S. J. Cryz, Jr., Lancet 344, 160 (1994).
23. R. Glück, R. Mischler, S. Brantschen, M. Just, B. Althaus, and S. J. Cryz, Jr., J. Clin. Invest. 90, 2491 (1992).
24. B. Mengiardi, R. Berger, M. Just, and R. Glück, Vaccine 13, 1306 (1995).
25. J. W. Yewdell and J. R. Bennink, Adv. Immunol. 52, 1 (1992).
26. R. N. Germain and D. H. Margulies, Annu. Rev. Immunol. 11, 403 (1993).
27. M. F. Bachmann, R. M. Zinkernagel, and A. Oxenius, J. Immunol. 161, 5791 (1998).
28. R. Bron, A. Ortiz, J. Dijkstra, T. Stegmann, and J. Wilschut, Meth. Enzymol. 220, 313 (1993).
29. I. Babai, S. Samira, Y. Barenholz, Z. Zakay-Rones, and E. Kadar, Vaccine 17, 1223 (1999).
30. A. M. Palache, R. Brands, and G. J. van Scharrenburg, J. Infect. Dis. 176 Suppl. 1, S20 (1997).
31. G. L. Peterson, Anal. Biochem. 83, 346 (1977).
32. E. G. Bligh and W. J. Dyer, Can. J. Biochem. Biophysiol. 37, 911 (1959).
33. C. J. F. Böttcher, C. M. van Gent, and C. Fiers, Can. J. Med. Sci. 24, 203 (1961).
34. A. Arkema, A. Huckriede, P. Schoen, J. Wilschut, and T. Daemen, Vaccine 18, 1327 (2000).
35. L. Bungener, K. Serre, L. Bijl, L. Leserman, J. Wilschut, T. Daemen, and P. Machy, Vaccine 20, 2287 (2002).
36. J. Wilschut, in: "Methodologie des Liposomes/Liposome Methodology" (L. D. Leserman and J. Barbet, eds.), p. 9. Editions INSERM Vol. 107, 1982.
37. T. Stegmann, P. Schoen, R. Bron, J. Wey, I. Bartoldus, A. Ortiz, J. L. Nieva, and J. Wilschut, Biochemistry 32, 11330 (1993).
38. P. Conne, L. Gauthey, P. Vernet, B. Althaus, J. U. Que, B. Finkel, R. Glück, and S. J. Cryz, Jr., Vaccine 15, 1675 (1997).
39. U. Glück, J.-O. Gebbers, and R. Glück, J. Virol. 73, 7780 (1999).
40. R. Glück, R. Mischler, P. Durrer, E. Fürer, A. B. Lanf, C. Herzog, and S. J. J. Cryz, J. Infect. Dis. 181, 1129 (2000).
41. L. Loutan, P. Bovier, B. Althaus, and R. Glück, Lancet 343, 322 (1994).
42. R. Zurbriggen and R. Glück, Vaccine 17, 1301 (1999).
43. F. Pöltl-Frank, R. Zurbriggen, A. Helg, F. Stuart, J. Robinson, R. Glück, and G. Pluschke, Clin. Exp. Immunol. 117, 496 (1999).